Congenital Adrenal Hyperplasia Clinical Trials
Here are the 6 most popular medical studies for congenital adrenal hyperplasia
Janus Kinase (JAK) Inhibitor
Ruxolitinib for Precancerous Breast Conditions
This trial is testing if the drug ruxolitinib can kill premalignant breast cells. Half the participants will get the drug and half will get a placebo for 15 days, then all will have surgery to remove the cells.
Hormone Therapy
Megestrol + Metformin for Endometrial Cancer Prevention
This trial is testing whether a combination of two drugs, megestrol acetate and metformin, is more effective than megestrol acetate alone in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer.
Laser Therapy
Thulium Fiber vs MOSES Holmium Laser for Enlarged Prostate
This trial is testing two procedures for benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. The procedures being tested are transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP). The study will compare the two procedures in terms of length of hospital stay, intraoperative outcomes, and postoperative outcomes.
Popular filter options for congenital adrenal hyperplasia trials
Enlarged Prostate Clinical Trials
View 24 Enlarged Prostate medical studies.
Beta-3 Adrenoceptor Agonist
Mirabegron +1 More for Overactive Bladder
This trial is testing a new OAB treatment combining a β3-adrenoceptor agonist (mirabegron) with an α-blocker. The goal is to see if this is a safe and effective treatment for OAB symptoms in male patients with BPH.
Thermal Therapy
Prolieve for Enlarged Prostate
The primary objective of the post-marketing study is to collect safety and effectiveness data for 5 years on subjects treated with Prolieve®. The collection of 5-year safety information will be used to evaluate the occurrence of any long-term side effects from the treatment. The collection of long-term effectiveness data on subjects treated with Prolieve® will provide information on the long-term effects of treatment and time to re- treatment (any treatment initiated for BPH since Prolieve'" treatment, including a second treatment with Prolieve").
CAH Clinical Trials
View 10 CAH medical studies.
Anti-diabetic drug
Metformin + LR-IUD for Endometrial Cancer
This trial is for women with biopsy-proven cancer or complex atypical hyperplasia who are not candidates for surgery, to see if adding metformin to standard levonorgestrel-releasing intrauterine device (LR-IUD) treatment helps.
Antiandrogen
Triple-Drug Therapy for Congenital Adrenal Hyperplasia
This trial is testing a new four-drug combination to see if it can normalize growth in children with congenital adrenal hyperplasia. The children will be followed until they reach their final adult height to see if the new combination is effective.
Congenital Adrenal Hyperplasia Clinical Trials With No Placebo
View 68 congenital adrenal hyperplasia medical studies that do not have a placebo group.
Aromatase Inhibitor
Exemestane for Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
This trial looks at how well exemestane works in treating patients with endometrial cancer or abnormal cell growth in the endometrium. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Hormone Therapy
Levonorgestrel IUS + Everolimus for Endometrial Cancer
This trial is testing whether a levonorgestrel-releasing intrauterine system, which is a type of progesterone-releasing device, is more effective when used with everolimus, a common drug used to prevent cell growth, in treating patients with atypical hyperplasia or stage IA grade 1 endometrial cancer.
Anti-diabetic drug
Metformin + LR-IUD for Endometrial Cancer
This trial is for women with biopsy-proven cancer or complex atypical hyperplasia who are not candidates for surgery, to see if adding metformin to standard levonorgestrel-releasing intrauterine device (LR-IUD) treatment helps.
View More Congenital Adrenal Hyperplasia Trials
See another 41 medical studies focused on congenital adrenal hyperplasia.
Frequently Asked Questions
Introduction to congenital adrenal hyperplasia
What are the top hospitals conducting congenital adrenal hyperplasia research?
In the realm of clinical trials for congenital adrenal hyperplasia, cutting-edge research is being conducted at several esteemed hospitals across the United States. Located in Bethesda, Maryland, the National Institutes of Health Clinical Center leads the pack with four active trials dedicated to this rare condition. This renowned institution has been at the forefront of congenital adrenal hyperplasia research since recording its first trial back in 1995. Meanwhile, at the University of Wisconsin Hospital and Clinics in Madison, three ongoing trials are currently underway to address this complex disorder. Although they have yet to conduct any prior studies on congenital adrenal hyperplasia, their commitment to breaking new ground is evident.
Similarly committed institutions include The University of North carolina at Chapel Hill and The University of Minnesota/Masonic Cancer Center. Both facilities have two active clinical trials exploring viable treatments for congenital adrenal hyperplasia but have not previously conducted any studies on this specific condition until now.
Even further afield lies Queen's Medical Center located amidst sunny Honolulu where researchers are also dedicating themselves to making strides against this challenging disorder through two current congenital adrenal hyperplasia clinical trials; although Queen's Medical Centre hasn’t explored such experiments before recently.
These top hospitals represent beacons of hope for individuals affected by congenital adrenal hyperplasia as well as testaments to medical advancement on a national scale. Their unwavering dedication toward understanding and treating this rare condition brings us ever closer to improving the lives of those touched by it while reinforcing that progress knows no geographical bounds
Which are the best cities for congenital adrenal hyperplasia clinical trials?
When it comes to congenital adrenal hyperplasia clinical trials, several cities emerge as leading hubs for research and development. Houston, Texas takes the top spot with 14 active trials exploring treatments like Levonorgestrel-Releasing Intrauterine System, Ruxolitinib, Prolieve, and more. New york City closely follows with 12 ongoing studies focused on interventions such as Crinecerfont and Decision Aid. Honolulu, Hawaii also shows promise with 11 active trials investigating options like Decision Aid and Levonorgestrel-Releasing Intrauterine System. Indianapolis, Indiana and Los Angeles, California each have 10 active trials studying various treatments including Tildacerfont and Abiraterone acetate. These cities offer individuals affected by congenital adrenal hyperplasia access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in treatment options.
Which are the top treatments for congenital adrenal hyperplasia being explored in clinical trials?
Clinical trials are illuminating promising treatments for congenital adrenal hyperplasia, offering hope to those affected by this condition. One standout contender is Chronocort, currently being explored in two active trials for congenital adrenal hyperplasia. Since its debut in 2007, it has been part of five clinical trials dedicated to addressing this disorder. Another potential breakthrough comes from Crinecerfont, a newcomer that has already caught the attention of researchers with two ongoing trials and two all-time studies focused on treating congenital adrenal hyperplasia since its introduction in 2020. As these investigations progress, new avenues may open up for individuals living with this challenging condition.
What are the most recent clinical trials for congenital adrenal hyperplasia?
New developments in clinical trials offer hope for individuals with congenital adrenal hyperplasia. One such trial focuses on sequential dosing, aiming to optimize treatment strategies for this condition. Another study investigates the potential benefits of APG-157 therapy, which could provide a valuable therapeutic option. Additionally, researchers are exploring the use of allogeneic umbilical cord tissue-derived mesenchymal stromal cells as a potential treatment approach. These groundbreaking studies demonstrate ongoing efforts to improve the management and outcomes associated with congenital adrenal hyperplasia.
What congenital adrenal hyperplasia clinical trials were recently completed?
A recent clinical trial investigating treatments for congenital adrenal hyperplasia has yielded promising results. In January 2019, the University of Minnesota successfully completed a trial evaluating the efficacy of subcutaneous hydrocortisone therapy. This important milestone brings us closer to improved management options for individuals with congenital adrenal hyperplasia, highlighting the dedication and progress made by researchers in this field.